<DOC>
	<DOCNO>NCT01941771</DOCNO>
	<brief_summary>The study hypothesis metronomic treatment efficient standard treatment .</brief_summary>
	<brief_title>Phase II Trial With Metronomic , Capecitabine Plus Oral Vinorelbine Metastatic Breast Cancer</brief_title>
	<detailed_description>Purpose : In open-label randomized phase II trial , patient metastatic Human Epidermal Growth Factor Receptor 2-negative breast cancer normal organ function sant WHO performance status &lt; 3 randomize receive either capecitabine ( day 1-14 ) plus vinorelbine oral ( day 1 8 ) capecitabine ( day 1-14 ) plus vinorelbine oral metronomic ( 3 day week ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Locally advanced metastatic Human Epidermal Growth Factor Receptor2Negative breast cancer WHO performance status &lt; 3 Former treatment Capecitabine Vinorelbine Patients receive one line chemotherapy metastatic disease Brain metastases Malabsorption syndrome Abnormal organ function pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>